~~<i id='58D9BC9FAB'><strike id='58D9BC9FAB'><tt id='58D9BC9FAB'><pre id='58D9BC9FAB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：Wikipedia 2025-09-28 15:55:26 - browse：65881

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Security flaws in third

leisure time

focus

leisure time

hotspot

explore

AdobeFiveyearsfromnow,whenpatientswalkintoadoctor’sofficepresentingsymptomsofalmostanyconditionyouca

WSS

A letter from the executive editor: The 2023 STATUS List

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Crowdfunding for unproven stem cell procedures spreads misinformation

The public health thinking behind the CDC’s new Covid guidance

Skip the lead apron during X

focus

knowledge

leisure time

Cancer drug shortages should be causing more outrage

Longer MASH drug regimen improved liver, Akero study finds

Hollywood unions extend contract negotiations for actors

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

The high cost of giving birth even with insurance

Security flaws in third

Guidelines to prevent youth baseball injuries need more muscle

Being 'nonadherent' patient made me a more empathetic doctor

DIEP, the 'gold standard' of breast reconstruction, is under threat

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

focus

$1 billion proposal to grow Boston, Massachusetts biotech

State of the Union pitch: Bigger Medicare drug price negotiations

For AI in health care standards, federal regulators join with industry group

Lack of health data on LGBTQ+ people has serious consequences

AstraZeneca lung cancer study comes in below expectations

First over

focus

leisure time

hotspot

explore